Roche/DeCode Genetics $200 mil. genomics deal to use Icelandic population data.
Executive Summary
ROCHE/DECODE GENOMICS DEAL TO FOCUS ON SCHIZOPHRENIA, DIABETES and 10 other diseases under an agreement announced by the companies Feb. 2. The five-year deal, which is valued at over $200 mil., is being heralded by the firms as "the largest human genomics deal ever." The initial focus of the collaboration is understood to be on a group of six diseases including adult onset diabetes and schizophrenia, with another group of six being researched at a secondary level. The agreement will cover four cardiovascular diseases, four psychiatric/neurologic disorders and four metabolic diseases.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: